WaveMan
WaveMan · Company
XLO · Xilio Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

XLO Xilio Therapeutics (XLO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001840233
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
14
13F, latest reported quarter

Xilio Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Xilio Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Shannon James Samuel
Director
BUY
2026-03-30 SECtraded 2026-03-26
5,000
$43.9K
-4.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 17, 2025.
  • +11.4% median (+11.4% mean) 90-day return after 2 previous buys.
  • The trade is 50.0% of the 10,000 shares held after it.
  • No other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shannon James Samuel bought about $43.9K of XLO on Mar 26, 2026, the largest insider purchase at the company since 2024; 14 funds added in the latest 13F quarter.
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
SELL
2026-01-05 SECtraded 2026-01-02
1,826
$1.2K
-17.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 2, 2025.
  • The trade is 28.7% of the 6,371 shares held after it.
  • 1 other insider sold within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, FINANCE AND ACCOUNTING Brennan Kevin M. sold about $1.2K of XLO on Jan 2, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 14 funds added in the latest 13F quarter.
Frankenfield Christopher James
Chief Financial Officer
SELL
2026-01-05 SECtraded 2026-01-02
7,030
$4.5K
-17.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 2, 2025.
  • The trade is 28.4% of the 24,766 shares held after it.
  • 1 other insider sold within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Frankenfield Christopher James sold about $4.5K of XLO on Jan 2, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 14 funds added in the latest 13F quarter.
Shannon James Samuel
Director
BUY
2025-06-18 SECtraded 2025-06-17
25,000
$17.2K
-17.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 16, 2025.
  • The trade is 35.7% of the 70,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shannon James Samuel bought about $17.2K of XLO on Jun 17, 2025; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.
Shannon James Samuel
Director
BUY
2025-06-18 SECtraded 2025-06-16
45,000
$31.0K
-17.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 45,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Shannon James Samuel bought about $31.0K of XLO on Jun 16, 2025; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.
26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 21 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
14 funds bought in last quarter
below 75% of Pharma & Biotech
Revenue
+589.9% year over year
more than 94% of Pharma & Biotech
Margin
-80.1% net margin
below 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.1% of the float short (float per yahoo 2026-10-26) · 44.5 days to cover · settled 2026-09-30
more than 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch XLO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.0%12M
-34%-19%-5%+10%2025-102025-122026-022026-042026-062026-082026-10 2026-03-26 · Shannon James Samuel bought $43.9K2026-01-02 · Frankenfield Christopher James sold $4.5K2026-01-02 · Brennan Kevin M. sold $1.2K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns XLO: institutional holders (13F)

13F holdings, latest reported quarter
Bain Capital Life Sciences Investors, LLC
664,021 sh
$6.4M
GILEAD SCIENCES, INC.
650,389 sh
$6.2M
ORBIMED ADVISORS LLC
592,300 sh
$5.7M
Stonepine Capital Management, LLC
451,988 sh
$4.3M
Frazier Life Sciences Management, L.P.
422,505 sh
$4.0M

Congress trades in XLO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

XLO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

XLO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$168.1K position · as of 2026-06-30
0.2%
iShares Micro-Cap ETF
$78.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$5.2K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$167.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$341.1K position · as of 2026-06-30
0.0%
Dimensional US Core Equity 1 ETF
$10.2K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 14 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

XLO financials

Revenue growth
+589.9%
XBRL, annual
Net margin
-80.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$64.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-34.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$61.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-55.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-15.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-31.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-132.3%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$43.8M$6.3Mn/an/a
Operating income-$42.0M-$60.6M-$79.1M-$89.1M
Net income-$35.0M-$58.2M-$76.4M-$88.2M
EPS (diluted)-4.19-15.24-2.78-3.22
Operating cash flow-$5.0M-$18.4M-$68.6M-$75.7M
Cash$137.5M$55.3M$44.7M$120.4M
SEC XBRL, fiscal years, as known on 2026-10-28

XLO Stock Sonar score 4/7 axes

Find similar shapesCompare

XLO ranks highest on growth (94th percentile) and profitability (62nd), and lowest on institutional and government (25th), among Pharma & Biotech peers.

Profitability
62
Inputs
  • Return on equity-55.0% · 50 pct, sector of 545
  • Return on assets-15.2% · 70 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-31.3% · 66 pct, sector of 576
Growth
94
Inputs
  • Revenue growth, YoY+589.9% · 94 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
25
Inputs
  • Funds adding, latest quarter14 · 25 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
31
Inputs
  • Short interest, % of float+12.1% · 33 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+15.4% · 28 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies